However, despite promising drug targets and success in pre-clinical testing, only two MEK inhibitors, trametinib (Mekinist) and cobimetinib (Cotellic), have been approved, both for the treatment of BRAF-mutant melanoma [3, 4, 24, 25]. Here, MAP2K7 is linked to melanoma.